

Miami Thyroid Oncology Symposium February 28-March 1, 2025


MIAMI
CANCER RESEARCH
CENTER



SINM
MI | SOCIETY OF
NUCLEAR MEDICINE
AND MOLECULAR IMAGING

Molecular Diagnosis & Therapy
RAI Theranostics & Dosimetry

Symposium Overview



Miami Thyroid Oncology Symposium stands at the forefront of innovation in thyroid cancer care, serving as a premier platform for discussing groundbreaking advancements in the field. The **7th Miami Thyroid Oncology Symposium (MTOS)** will be held on February 28 and March 1, 2025, Jointly sponsored by **Miami Cancer Research Center (MCRC)** and **Society of Nuclear Medicine and Molecular Imaging (SNMMI)**. MTOS will bring together world-leading experts to discuss the transformative advances in the diagnosis and treatment of thyroid cancer, emphasizing the pivotal role of genomics, molecular diagnostics and therapy. The symposium bridges the genomic paradigm with the enduring importance of traditional approaches, including surgery and radioactive iodine (RAI) theranostics. The new transformed paradigm comes with new definitions such as ***mis-differentiated thyroid cancer*** and ***RAI-indifferent thyroid cancer***

The symposium emphasizes a transformative shift in thyroid cancer management, integrating innovative ***molecular diagnostics and therapeutics*** with established surgical and nuclear approaches to redefine standards of care and improve patient outcomes. Attendees will gain critical insights into how molecular diagnostics navigate rational surgical decision-making and enhance the effectiveness of radioactive iodine (RAI) theranostics. Experts from various disciplines will guide thought-provoking lectures and dynamic panel discussions, addressing advancements in diagnostic and therapeutic modalities, including ***oncoprotein-targeted molecular therapies, immunotherapy, and solutions to common clinical challenges*** faced by practitioners. The interactive discussions will foster collaborative exchanges, focusing on the practical application of evolving strategies in clinical practice. Designed for meaningful engagement, the symposium's format ensures a rich learning experience. The first day will feature comprehensive lectures by globally recognized leaders in thyroid oncology, presenting cutting-edge research and clinical applications. On the second day, the format shifts to interactive panel discussions and Q&A sessions, encouraging active participation and exploration of practical implications from the latest findings and evidence-based recommendations.

Faculty-led sessions will critically examine the ***American Thyroid Association (ATA) guidelines*** in the context of recent scientific advancements, offering actionable insights for real-world application. Contributions from surgical oncologists, endocrinologists, pathologists, nuclear medicine specialists, and other experts will provide a multidisciplinary perspective that reflects the complexity of thyroid cancer care. Central to the discussions will be the critical role of radioactive iodine theranostics and ***redifferentiation strategies*** for treating RAI-indifferent thyroid cancers with special emphasis on ***dosimetry***. The symposium will take place in person, with limited virtual access available for international participants. Bringing together pioneers in thyroid oncology, this event serves as an invaluable platform for clinicians, researchers, and healthcare professionals to stay at the forefront of thyroid cancer care while contributing to the evolution of the field during this exciting era of medical innovation.

The symposium is co-sponsored by MCRC and SNMMI

Seza Gulec

Seza Gulec, MD, FACS, FACNM, Symposium Director

Symposium Faculty

Seza Gulec, MD, FACS, FACNM, Symposium Director

Professor of Surgery and Nuclear Medicine
President of Medical Staff, HCA Florida, Aventura Hospital
CEO and Chairman of the Board, Miami Cancer Research Center

Aziz Aliyev, MD, PhD

Professor, Head and Neck Oncology at National Cancer Center, Baku, Azerbaijan
Medical Dean, Sechenov University Baku Branch, Baku, Azerbaijan

Dale Bailey, PhD

Professor and Attending Physicist
University of Sydney, Australia

Richard P. Baum, MD, PhD

President Academy, International Centers for Precision Oncology (ICPO)
Chairman, Scientific Board ICPO
Professor emeritus Goethe University Frankfurt

Victor Bernet, MD, FACE, FACP

Director, Endocrinology, Diabetes and Metabolism Fellowship Program
Consultant, Division of Endocrinology, Mayo Clinic Florida
Professor, Mayo Clinic College of Medicine and Science,
Former President, ATA

Maria Cabanillas, MD

Professor, Endocrine Neoplasia & Hormonal Disorders,
The University of Texas MD Anderson Cancer Center, Houston, TX

Daryl Eber, MD

Chief Medical Officer and Founder 3T Radiology & Research
Miami, FL

James A. Fagin, MD

Division Head, Subspecialty Medicine, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College, New York, NY

David Filippi, MD

Neurologist and Clinical Neuroscientist
Director, Stroke Program, HCA Florida, Aventura Hospital

Laura Fugazzola, MD

Professor of Endocrinology
Department of Pathophysiology and Transplantation, University of Milan,
President of the European Thyroid Association

Luca Giovanella, MD

Professor of Nuclear Medicine and Thyroid Center - University Hospital of Zurich, Zurich,
Switzerland, Department of Nuclear Medicine and Thyroid Center - Gruppo Ospedaliero Moncucco,
Lugano, Switzerland, Chair, Thyroid committee, EANM

Symposium Faculty

Alan Ho, MD, PhD

Chief, Head and Neck Medical Oncology
Memorial Sloan Kettering Cancer Center, New York, NY

Akira Miyauchi, MD, PhD.

President-Emeritus Department of Surgery Kuma Hospital, Kobe, Japan

Helen Nadel, MD

Clinical Professor, Pediatric Radiology, Director of Pediatric Nuclear Medicine including PET/MRI
Stanford Health Care; Stanford Medicine Children's Health
SNMMI Immediate Past President

Yuri E. Nikiforov, MD, PhD

Professor of Pathology
Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA

Douglas Van Nostrand, MD, FACP, FACP, FACNP

Director, Nuclear Medicine Research, MedStar Health Research Institute
MedStar Washington Hospital Center
Professor of Medicine, Georgetown University

Andrew Prideaux, PhD

Attending Physicist, MCRC, Miami, FL

Andrew Scott, MD

Professor, Department of Molecular Imaging and Therapy, Austin Health
Tumor Targeting Laboratory, Olivia Newton-John Cancer Research Institute
University of Melbourne, and La Trobe University, Melbourne, Australia

Jean-Luc C. Urbain, MD, PhD, FASNC

Professor of Radiology/Nuclear Medicine and Medicine
President-elect of the Society of Nuclear Medicine and Molecular Imaging

Erivelto Volpi, MD, PhD

Head and Neck Surgeon, Oswaldo Cruz German Hospital
Educational Committee, North American Society of Interventional Thyroidology
Chair, International Advisory Service, American Head and Neck Society

Richard Wahl, MD, PhD

Professor at Mallinckrodt Institute of Radiology at Washington University School of Medicine

Pat Zanzonico, PhD

Attending Physicist, MSKCC, New York, NY

PLENARY SESSION
Friday, February 28, 2025
07:30-13:00
CLINICAL PERSPECTIVES TO GENOMICS AND MOLECULAR THERANOSTICS
Moderators: Seza Gulec and Yuri Nikiforov

07:30: The New Terms and Concepts in Thyroid Oncology
Seza A Gulec

08:00: The Science, Craft and Art of Complex Thyroid Surgery
Aziz Aliyev

08:30: Active Surveillance for Management of Papillary Microcarcinoma:
More than 30 years of experience
Akira Miyauchi

09:00: Molecular Diagnostics: Analysis of over 50,000 studies
Yuri Nikiforov

09:30: Discussion and Coffee Break

10:00: Molecular Therapies in Mis-differentiated, Poorly and Undifferentiated Thyroid Cancers
Maria Cabanillas

10:30: Immune-mediated response of advanced thyroid cancers to MAPK inhibitors
James Fagin

11:00: The Theranostic role for molecular testing in Bethesda 6 cytology and Surgical Pathology
Yuri Nikiforov

11:30: Discussion and Luncheon Lectures

12:00: Radiofrequency Ablation of Thyroid Nodules and Cancer
Erivelto Volpi

12:30: PET/CT Molecular Imaging in Thyroid Cancer
Daryl Eber



PLENARY SESSION

Friday, February 28, 2025

13:00-17:30

RAI-REFRACTORY/INDIFFERENT THYROID CANCER AND REDIFFERENTIATION

Moderators: Douglas VanNostrand and Maria Cabanillas

13:00: RAI Refractory Thyroid Cancer
Douglas VanNostrand

13:30: Redifferentiating mis-differentiated thyroid cancers: MD Anderson Experience
Maria Cabanillas

14: 00: Redifferentiation Modulating ERK output and Beyond, MSKCC Experience
Alan Ho

14:30: The Key Role for Dosimetry for RAI treatment Response Reporting
Seza A Gulec

15:00: **Discussion and Coffee Break**

15:30: Australian Experience with Redifferentiation therapy
A. Scott

16:00: RAI Radio-safety and Efficacy in Pediatric Patients
I-131 MIBG and I-131 NaI Experiences:
Helen Nadel

16:30: Progress in Nuclear Theranostics, Invitation to MARS SHOT Event
Richard Wahl

17:00: **Discussion**



Invitation Only



PLENARY SESSION

Saturday, March 1, 2025

07:30-13:00

TRANSLATIONAL THYROID ONCOLOGY AND MULTI-DISCIPLINARY VIEWS

Moderators: Jean-Luc Urbain and Victor Bernet

07:30: The Journey of Thyroidology

Cristina Benites

Young Scholar Award

08:00: Bridging Molecular Oncology to Clinical Oncology

Seza Gulec

08:30: Modulation of Oncophysiology through ERK signaling

Alan Ho

09:00: Impact of clonal hematopoiesis on the biology and response to therapy of thyroid cancer

James Fagin

09:30: Discussion and Coffee Break

10:00: The position and Pulse of ETA in the New Genomics-guided Management Paradigm

Laura Fugazzola

10:30: The position and Pulse of EANM in the New Genomics-guided Management Paradigm

Luca Giovanella

11:00: The position and Pulse of SNMMI in the New Genomics-guided RAI Theranostics

Douglas Van Nostrand

11:30 Exploring the Utility of Thyroid Cancer-related Genomic-Guided Management Strategies

Victor Bernet

12:00: Discussion and Luncheon Lectures

12:00: Theranostics 2025: Thyroid and Beyond

Richard Baum

Science behind GLP-1 and Thyroid-associated Concerns

David Filippi



MULTIDISCIPLINARY / INTERSOCIETAL TUMOR BOARD

Saturday, March 1, 2025

13:00-15:00

Moderators: Jean-Luc Urbain and Alan Ho

13:00-15:00

Multi-disciplinary, Multi-societal Tumor Board

*A Clash of Guidelines
Inter-societal Consensus and Concessions
Clinical Trials Solutions*

15:00: Discussion and Coffee Break

I-124 PET/CT DOSIMETRY WORKSHOP

Saturday, March 1, 2025

15:30-17:30

Moderators: Douglas Van Nostrand and Seza Gulec

15:30: The New York (MSKCC) Protocol

Pat Zanzonico

16:00: The Miami (MCRC) Protocol

Andrew Prideaux

16:30: The Australian Protocol

Dale Bailey



Invitation Only

MTOS Committees

STEERING COMMITTEE

Seza Gulec, MD, FACS, FACNM,

Professor of Surgery and Nuclear Medicine
CEO and Chairman of the Board, Miami Cancer Research Center
President of Medical Staff, HCA Florida, Aventura Hospital

Yuri E. Nikiforov, MD, PhD

Professor of Pathology
Vice-Chair Department of Pathology, Director, Division of Molecular & Genomic Pathology
University of Pittsburgh Medical Center, Pittsburgh, PA

Douglas Van Nostrand, MD, FACP, FACNP

Professor of Medicine at Georgetown University Medical Center in Washington, DC
Director of Nuclear Medicine at MedStar Health Research Institute

Jean-Luc C. Urbain, MD, PhD, FASNC

Professor of Radiology/Nuclear Medicine and Medicine
President-elect of the Society of Nuclear Medicine and Molecular Imaging

ORGANIZING COMMITTEE

Dahlia Mohammed, MS

Vice President of Operations, Miami Cancer Research Center, Miami, FL
Symposium Coordinator

Cristina Benites

Vice President of R&D and Informatics, Miami Cancer Research Center, Miami, FL
Symposium Coordinator

Sam Angel

Director of Communications, Miami Cancer Research Center, Miami, FL
Symposium Coordinator

Paul Perales-Villaruel, MD

Chief Operating Officer, Miami Cancer Research Center, Miami, FL
Symposium Coordinator

Sharon Jenkins, EdD

Senior Director of Development and Marketing, SNMMI, Reston, VA
SNMMI-MCRC Liaison

REGISTRATION

In-Person Attendance

Categories:

General Admission (Physicians and Scientists): \$225

Nurses and Midlevel Providers: \$100

Students and Physicians in Training: \$75

Miami Thyroid Oncology Consortium Members: Exclusive Rates

On-line Attendance

\$450 All Categories

Why attend in person?

Attending in person adds a special touch to the experience. You'll get to connect directly with leading professors, take part in engaging discussions and debates, and join unique special events that bring the program to life. Plus, you'll enjoy complimentary food and drinks to keep you fueled throughout the day. As an added perk, in-person attendees also receive digital access to the program materials, so you can revisit anything you want at your own pace. And with discounted registration fees, it's an affordable way to make the most of everything this event has to offer. Join us in person to connect, learn, and make this event truly memorable.

SYMPOSIUM ORGANIZATION

MTOS is organized by Miami Cancer Research Center (MCRC), a scientific and charitable organization that performs and supports cancer research, organizes educational events and provides support for cancer care at institutional and individual levels. The mission of the MCRC is to take part in the global fight against cancer through research, education and patient care support. The symposium is endorsed and supported by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)

CONTINUOUS MEDICAL EDUCATION CREDITS

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Dade County Medical Association and Miami Cancer Research Center. The Dade County Medical Association is accredited by the Florida Medical Association to provide continuing medical education for physicians. DCMA designates this educational activity for a maximum of 16 AMA PRA Category 1 credit(s)[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

SYMPOSIUM SUPPORT

This symposium is supported by the following academic and industry partners

MIAMI CANCER RESEARCH CENTER Academic Sponsor



SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING Academic Sponsor



PLATINUM SPONSOR JUBILANT RADIO PHARMACY

GOLD SPONSOR 3T RADIOLOGY AND RESEARCH

SILVER SPONSORS EISAI

THERMOFISHER

GALATEA BIO

BRONZE SPONSOR HERMES

CONTRIBUTORS CARIS LIFE SCIENCES ETHICON INC SONIC HEALTHCARE USA

CONFERENCE VENUE

FIU Kovens Conference Center

The MTOS will be held Kovens Conference Center at the FIU's Biscayne Campus, 33181, North Miami Beach, FL, 33181. The symposium welcomes all professionals involved or interested in the care of patients with thyroid nodules or cancer. It is also open to public who are keen to learn the state-of-the-art technology in thyroid cancer diagnosis and treatment. The headquarter hotel is "Marenas Beach Resort" in Sunny Isles Beach. The symposium venue, Kovens Conference Center is close to many hotels with different packages and offers.



Kovens Conference Center



Marenas Beach Resort